Abbvie Inc Stock Price, News & Analysis

AbbVie (ABBV) and Xilio Therapeutics (XLO) have announced a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies. The partnership leverages Xilio's proprietary technology platform for developing tumor-activated biologics, including masked T-cell engagers.

The collaboration aims to combine AbbVie's oncology expertise with Xilio's technology to create next-generation cancer treatments focused on tumor-selective activation while minimizing systemic adverse events. Under the agreement terms, Xilio will receive $52.0 million in total upfront payments, including a $10.0M equity investment, and will be eligible for up to $2.1 billion in contingent payments plus tiered royalties.

AbbVie (ABBV) has received FDA approval for EMBLAVEO™, the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. The drug is approved in combination with metronidazole for treating complicated intra-abdominal infections (cIAI) in adults with or no alternative options.

EMBLAVEO combines aztreonam and avibactam to combat Gram-negative bacteria, including resistant strains that produce Metallo-β-lactamases (MBLs). The approval was supported by the Phase 3 REVISIT study and prior findings on aztreonam's efficacy in cIAI treatment.

The drug received FDA's Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation in 2019, granting priority review and five-year regulatory exclusivity extension. Commercial availability is expected in Q3 2025.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced a nationwide open casting call for the Faces of Natrelle® campaign, seeking women who have undergone breast reconstruction or augmentation to share their stories. The initiative, running through February 28, 2025, extends the Natrelle® For Every BODY platform and aims to promote inclusivity and diversity.

Natrelle®, recognized as the #1 selected breast implant by leading U.S. physicians, offers the largest range of breast implant options. The campaign targets women aged 22 or older who have recently scheduled or undergone Natrelle® procedures. Important safety information highlights that breast implants are not lifetime devices and may require additional surgeries due to complications, including risks of BIA-ALCL cancer and various systemic symptoms.

Allergan Aesthetics, an AbbVie company, has expanded its LIMITLESS initiative with new content featuring interviews with Dr. Caroline Glicksman and Dr. Melinda Haws, both immediate past presidents of prestigious aesthetic societies. The LIMITLESS program, founded in 2020 in partnership with multiple surgical societies, aims to promote women surgeons and break down barriers for their advancement to leadership positions.

The initiative includes a docuseries on YouTube, a podcast series, and the upcoming LIMITLESS Leaders' Summit in Boston (February 5-6, 2025). The platform features successful women surgeons sharing their experiences and insights, with the Presidential Series highlighting various past presidents of major plastic surgery organizations. The fourth season of the LIMITLESS podcast is set to launch in early 2025, offering monthly episodes focused on career development and professional guidance.

AbbVie (ABBV) reported full-year 2024 financial results with net revenues of $56.334 billion, up 3.7% on a reported basis. The company's diluted EPS was $2.39 (GAAP), down 12.1%, while adjusted EPS was $10.12, down 8.9%.

Key portfolio performance includes: Immunology revenues of $26.682 billion (+2.1%), with Skyrizi reaching $11.718 billion and Rinvoq $5.971 billion; Oncology revenues of $6.555 billion (+10.8%); Neuroscience portfolio at $8.999 billion (+16.6%); and Aesthetics portfolio at $5.176 billion (-2.2%).

Looking ahead, AbbVie provided 2025 adjusted EPS guidance of $12.12-$12.32 and raised its 2027 combined sales outlook for Skyrizi and Rinvoq to over $31 billion. The company expects high single-digit compound annual revenue growth through 2029.

Allergan Aesthetics, an AbbVie Company, has launched the new AA Signature program at IMCAS World Congress 2025, introducing an innovative approach to aesthetic treatment planning. The program focuses on delivering personalized, patient-centric solutions through their advanced product portfolio.

Research shows that 8 in 10 patients proceed with treatment following holistic consultation, and clinics using multi-area treatment plans experience a 68% higher retention rate. The program addresses three key patient needs: Lift (structure and skin firmness), Definition (enhanced facial angles), and Skin quality (smoothness and hydration).

The initiative includes advanced training and education modules for healthcare providers (HCPs), supporting them with combination product use and comprehensive educational programs. The program will be gradually introduced worldwide to reflect new trends, products, and indications.

Allergan Aesthetics, an AbbVie company, announces the launch of its new AA Signature Program at IMCAS World Congress 2025 in Paris. The program offers a personalized approach to aesthetic treatment planning, focusing on lift, definition, and skin quality improvements.

Research indicates that 80% of patients proceed with treatments following holistic consultations, and clinics using multi-area treatment plans see a 68% higher retention rate. The congress will feature an AMI symposium with live injection demonstrations, expert presentations, and an interactive exhibition booth.

The event includes a Medical Symposium on 'Mastering the Lower Face and Neck' and Meet the Experts sessions featuring renowned professionals like Dr. Jean Carruthers, who pioneered the cosmetic use of neuromodulators. The Allergan Aesthetics booth (E130, Level 1) will serve as a discovery hub for the new program and product portfolio.

AbbVie (NYSE: ABBV) has completed its acquisition of Nimble Therapeutics, strengthening its pipeline and R&D capabilities in immunology. The acquisition brings two key assets: a potential novel oral peptide IL23R inhibitor in preclinical development for psoriasis treatment, and Nimble's proprietary peptide synthesis, screening, and optimization platform.

The platform utilizes proprietary technology to accelerate the discovery and optimization of oral peptide candidates across various targets. Following the completion, Nimble has been integrated into AbbVie, with its team joining AbbVie's efforts to advance autoimmune disease treatments.

AbbVie (NYSE: ABBV) and Neomorph have announced a collaboration and option-to-license agreement to develop molecular glue degraders for oncology and immunology targets. The partnership combines AbbVie's expertise in drug development with Neomorph's molecular glue discovery platform.

Molecular glue degraders represent a novel class of small molecules designed to selectively target and trigger degradation of proteins involved in cancer growth and immune system dysregulation, including previously 'undruggable' proteins.

Under the agreement terms, Neomorph will receive an upfront payment and is eligible for up to $1.64 billion in option fees and milestones, plus tiered royalties on net sales.